tbuckley/cabot-search huggingface dataset:
Antibodies in Normal and Leukemic Cats to Feline Oncornavirus-Associated Cell Membrane Antigens 2
Authors: William Jarrett, Myron Essex, Lindsay Mackey, Oswald Jarrett, Helen Laird
Journal: JNCI Journal of the National Cancer Institute (1973)

We described the serologic findings in 22 cats with naturally occurring, well-characterized hematopoietic neoplasms and in 28 normal adult cats. The test was an indirect fluorescentantibody technique for feline oncornavirus-associated cell membrane antigen of A, B, and C subgroup specificities. Thirty-nine percent of normals and forty-five percent of cats with neoplasms had antibodies.
Dimethylnitrosamine Demethylase Activity In Fetal, Suckling, and Maternal Mouse Liver and Its Transplacental and Transmammary Induction by Polychlorinated Biphenyls&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Raymond A. Jannetti, Lucy M. Anderson
 5
Journal: JNCI Journal of the National Cancer Institute (1981)

Oxidative demethylation of dimethylnitrosamine (DMN) was detectable with liver homogenate preparations from fetal mice (noninbred Swiss) by day 16 of gestation; this activity increased to adult levels by postnatal day 7. Treatment of pregnant mice with a mixture of polychlorinated biphenyls (PCB's), 500 mg Aroclor 1254/kg, on the fast day of gestation caused a large elevation in DMN demethylase activity in tile livers of their sucklings, relative to the normal ontogenic increase, reaching a maximum at postnatal day 21. Foster nursing experiments showed that this inductive effect was due primarily to lactational delivery of the PCB's. DMN demethylase activity in the maternal livers was significantly lower than normal during pregnancy. The mothers' livers were also less responsive to DMN demethylase induction by PCB's during the last 5 days of gestation in comparison with the response earlier in pregnancy or just after delivery. In the livers of the mothers, induced activity resulting from treatment with PCB's on day 19 of gestation reached a maximum on postnatal days 4–7 and declined to normal levels by the time of weaning.
GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler
Authors: Motoki Takaku, Sara A. Grimm, Takashi Shimbo, Lalith Perera, Roberta Menafra, Hendrik G. Stunnenberg, Trevor K. Archer, Shinichi Machida, Hitoshi Kurumizaka, Paul A. Wade
Journal: Genome biology (2016)

Transcription factor-dependent cellular reprogramming is integral to normal development and is central to production of induced pluripotent stem cells. This process typically requires pioneer transcription factors (TFs) to induce de novo formation of enhancers at previously closed chromatin. Mechanistic information on this process is currently sparse. Here we explore the mechanistic basis by which GATA3 functions as a pioneer TF in a cellular reprogramming event relevant to breast cancer, the mesenchymal to epithelial transition (MET). In some instances, GATA3 binds previously inaccessible chromatin, characterized by stable, positioned nucleosomes where it induces nucleosome eviction, alters local histone modifications, and remodels local chromatin architecture. At other loci, GATA3 binding induces nucleosome sliding without concomitant generation of accessible chromatin. Deletion of the transactivation domain retains the chromatin binding ability of GATA3 but cripples chromatin reprogramming ability, resulting in failure to induce MET. These data provide mechanistic insights into GATA3-mediated chromatin reprogramming during MET, and suggest unexpected complexity to TF pioneering. Successful reprogramming requires stable binding to a nucleosomal site; activation domain-dependent recruitment of co-factors including BRG1, the ATPase subunit of the SWI/SNF chromatin remodeling complex; and appropriate genomic context. The resulting model provides a new conceptual framework for de novo enhancer establishment by a pioneer TF.
Randomized comparison of “neutropenic” and non-neutropenic diet in pts undergoing remission induction therapy for AML
Authors: A. Gardner, G. Mattiuzzi, S. Faderl, G. Borthakur, G. Garcia-Manero, E. Estey
Journal: Journal of Clinical Oncology (2008)

7052 Background: A “neutropenic diet,” e.g. one interdicting use of fresh fruits and vegetables, is often used to prevent infection in pts with AML. Although such a diet potentially entails inconvenience, its value is uncertain. Methods: 153 pts admitted to a HEPA-filtered room (PE) to receive remission induction therapy for newly-diagnosed AML were randomized to a diet containing no raw fruits or vegetables (“cooked”) or to a fresh fruit, fresh vegetable containing diet (“raw”). Stratification was based on the patients' “early risk of mortality” (ERM) score (Leukemia 1989; 3: 257–63). All patients received prophylaxis with levofloxacin, valcyclovir, and itraconazole or voriconazole and remained on study until they were discharged from the PE, typically upon recovery of their neutrophil count. If early stopping did not occur, 188 patients were to be randomized using a Bayesian design that monitored major infection and death; if the true probability of major infection (or death) was 20% on the cooked arm and 40% on the raw arm the probability that the cooked arm would be selected as superior was 83%. Results: 78 pts were randomized to the cooked arm and 75 to the raw arm. The 2 groups were similar with respect to age (median 64), ERM score, type of chemotherapy, and days at risk (median days on study 24). 29% of pts in the cooked and 35% of pts in the raw group developed a major infection (p = 0.60), and time to development of a major infection and survival time were likewise similar in the 2 groups. The incidence of pneumonia ± bacteremia or fungemia (b/f) was 20% in the cooked group vs. 12% in the raw group, while b/f ± pneumonia was seen in 14% of the cooked group and 30% of the raw group. The organisms responsible for isolated pneumonia were generally unidentified, while organisms resident in the gut were cultured from blood in 6% of the cooked and 15% of the raw group (p = 0.12). In no pts were typical food borne pathogensisolated. Fever of unknown origin occurred in 51% of the cooked and 36% of the raw group. Conclusion: In pts treated in a PE a neutropenic diet did not prevent major infection or death. These results might encourage performance of a similar trial undertaken outside a PE. No significant financial relationships to disclose.
Weekly cisplatin/irinotecan and radiotherapy (RT) in patients with locally advanced esophageal cancer : multicenter FFCD phase II trial
Authors: P. Michel, X. Mirabel, M. P. Galais, L. Dahan, T. Conroy, E. Boucher, C. Oprea, B. Paillot
Journal: Journal of Clinical Oncology (2005)

4060 Background: A recent phase I have showed that weekly cisplatin, irinotecan and concurrent RT can be administered with moderate toxicity (J Cin Oncol 2003;21:2926–32). Methods: patients (pts) with no prior treatment and esophageal squamous cell carcinoma (SCC) or adenocarcinoma (ADK), stage I to III (AJCC 1983), performance status ≤2, caloric intake >1500 Kcal/d and weight loss<15% were included. Chemotherapy with weekly cisplatin 30 mg/m2 and irinotecan 60 mg/m2 was administered at day 1,8,22,29,43,50,64 and 71. Concurrent RT was delivered weeks 7 to 11 (day 43 to 75) with 50Gy in 25 fractions/5 weeks. Response was assessed by clinical examination, esophageal endoscopy with biopsy, CT scan at weeks 21. Complete response was defined as no tumor detectable on esophagus endoscopy with absence of malignant cells on biopsies and no appearance of distant metastasis on CT scan. In all other cases, the pts were considered as non responders. Results: from 1/2003 to 12/2003, 43 pts were included, 10 stage I, 19 stage II and 14 stage III (38 SCC, 4 ADK, 1 undifferentiated). Mean age was 59.2 y (range 44–79). 32/43 pts performed treatment as planned with all courses of chemotherapy. All pts were included in analysis.Grade 3 toxicity occurred in 21/43 pts: neutropenia 9, thrombopenia 3, anemia 4, vomiting 1, mucosite 1, diarrhea 1, cardiac failure 2, renal failure 1. Grade 4 toxicity occurred in 7/43 pts: neutropenia 2, febrile neutropenia 1, sepsis during neutropenia 1, diarrhea 1, cardiac failure 1, hepatic failure 1. One toxic death was occurred (diarrhea grade 4). The complete endoscopic response rate with absence of malignant cells on biopsies was 53.5% (CI95%:38.5–68.5%). The one year survival rate will be available at the meeting. Conclusions: cisplatin-irinotecan-RT is an active treatment for pts with non operable esophageal cancer. Future study with EGFr inhibitor is considered to increase response rate. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.
Authors: Priyanka Sharma, Bruce F. Kimler, Jennifer R. Klemp, Claire Ward, Carol Sue Connor, Marilee McGinness, Joshua Matthew Varghise Mammen, Jamie Lynn Wagner, Amanda Leigh Amin, Carol J. Fabian, Roy A. Jensen, Andrew K. Godwin, Qamar J. Khan
Journal: Journal of Clinical Oncology (2015)

1092 Background: Randomized studies have demonstrated that Neoadjuvant Chemotherapy (NAC) is equivalent to adjuvant chemotherapy (AdjC) in operable breast cancer (BC). However, the differential impact of NAC vs AdjC on outcomes in various BS subtypes is not known. Specifically, the impact of AdjC vs NAC BC outcomes in small (T1-2) clinically node negative (NN) triple negative breast cancer (TNBC) is not known. Aim: To evaluate the impact of NAC vs. AdjC on BC recurrence and RFS in NN T1-2 TNBC utilizing data from a prospective registry. Methods: 316 stage I-III TNBC patients enrolled in a multisite IRB approved registry between 2011 and 2014. Clinical, demographic, chemotherapy and recurrence information was collected. This study was restricted to analysis of registry participants with T1-2, NN disease. RFS was estimated according to the Kaplan-Meier method and compared among groups with log-rank statistic. Results: 146 patients with NN T1-2 TNBC enrolled on the registry since 2011. Patients underwent either NAC (67/146, 46%) or AdjC (79/146, 54%) at the discretion of treating physician. For the 146 eligible patients, median age was 55 yrs (range 24-80), 14%: African American, 49% had T1 and 51% had T2 disease. Almost all patients received Anthracyline and/or taxane containing chemotherapy (AdjC: 95%, NAC: 100%). Compared to AdjC patients, NAC patients were younger (median age 52 vs 58 yrs, p = 0.015), more likely to have T2 tumors (76% vs 29%, p < 0.001), more likely to be treated at academic center (91% vs 24%; p < 0.001) and more likely to have received > 4 cycles of chemotherapy (85% vs 53%; p = 0.001). PCR was observed in 55% of NAC cohort (37/67). Overall, at a median follow of 37 months (6-89) there have been 8 (5%) recurrences (1/67 in NAC group & 7/79 in AdjC group). RFS in NAC group was 98% vs. 91% in AdjC group (p = 0.07). On multivariate Cox regression analysis, AdjC (compared to NAC) was the only factor demonstrating a trend towards worse RFS (p = 0.080). Conclusions: Patients with NN, T1-2 TNBC demonstrate excellent outcome when treated with NAC (98% RFS). Compared to AdjC, NAC was associated with a trend towards better RFS in NN T1-2 TNBC. In patients with clinically node negative TNBC, NAC should be compared to AdjC prospectively.
Bone Marrow Transplantation for Chronic Granulocytic Leukemia&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: P Lehn, A Devergie, M Benbunan, N Lemercier, C Raffoux, C Rabian, E Vilmer, O Azogui, T Irti, E Gluckman
Journal: JNCI Journal of the National Cancer Institute (1986)

Thirty-seven patients with chronic granulocytic leukemia have been treated with supralethal chemoradiotherapy followed by transplantation of bone marrow from HLA-identical donors. All patients showed engraftment, and the Philadelphia chromosome (PH1) disappeared in each case. Four patients had syngeneic grafts before blast crisis and are still alive; 2 are in remission not maintained by therapy, and 2 others are receiving chemotherapy after having relapsed in the chronic phase. Thirty-three patients had allogeneic grafts; only 2 received the grafts during blast crisis, and neither is a long-term survivor. Of the 13 patients who had grafts in the accelerated phase, 6 died of complications related to the transplantation, and 1 died after a myeloblastic relapse. Thus 6 patients are in unmaintained remission with a median follow-up of 13 months. Eighteen patients received grafts in the chronic phase. All 10 survivors are in unmaintained remission with a median follow-up of 14 months; in this group, no patient has relapsed. The granulocytic hyperplasia of the chronic phase can be more effectively ablated than established blastic leukemia. The mortality rate of transplant-related complications must be weighted against the typical rate of progression of chronic granulocytic leukemia. Although a longer follow-up period is needed for full evaluation, bone marrow transplantation may now be offered to patients in the chronic phase in an attempt to achieve long-term survival or cure of more than one-half of these patients.
The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice
Authors: Manuela Donalisio, Paola Quaranta, Flavia Chiuppesi, Mauro Pistello, Valeria Cagno, Roberta Cavalli, Marco Volante, Antonella Bugatti, Marco Rusnati, Elisabetta Ranucci, Paolo Ferruti, David Lembo
Journal: Biomaterials (2016)
Use of the Working Formulation for Non-Hodgkin's Lymphoma in Epidemiologic Studies: Agreement Between Reported Diagnoses and a Panel of Experienced Pathologists&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: F Dick, S VanLier, P Banks, G Frizzera, G Witrak, R Gibson, G Everett, L Schuman, P Isacson, G O'Conor
Journal: JNCI Journal of the National Cancer Institute (1987)

Independent review of slides of 668 cases of non-Hodgkin's lymphoma (NHL) by a panel of 4 experienced pathologists using the Working Formulation (WF) allowed determination of the agreement between reported diagnoses and panel review of slides. The panel agreed with the reported diagnosis of NHL in 93% of cases, but with the NHL subtype in only 55% of cases overall. The ability of the panelists to agree among themselves, however, was only slightly better than the panelists' agreement with the reported diagnosis (60% vs. 54%, respectively). Agreement of the panel with the reported subtype diagnosis varied from 14% to over 90%. The best agreement was with small lymphocytic lymphoma and follicular subtypes. Conclusions from this study are: 1) The WF functions well as a common language for translation and comparison of diagnoses of subtypes of NHL. 2) Relative to time and cost involved, panel review using only light microscopy may not be useful in epidemiologic studies of NHL. 3) Small lymphocytic and follicular subtypes of NHL can be used more confidently in epidemiologic studies than can other subtypes whether the subtyping is done from abstracted reports or by panel review.
TCT-710 Prognostic Impact of Left Main Coronary Artery Revascularization in Multivessel Coronary Artery Disease
Authors: Jung-Min Ahn, Shin-Eui Yoon, Seung Mo Kang, Uk Jo, Hyun Woo Park, Young-Rak Cho, Gyung-Min Park, Won-Jang Kim, Jong-Young Lee, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2012)
Abstract 12191: Efficacy and Safety of Long-Term Treatment With AMG 145 Monotherapy
Authors: Eli M Roth, Ransi Somaratne, Michael Bolognese, Michael J Lillestol, Pernille Lundqvist, Harold Bays, Phillip D Toth, Jae B Kim, Jingyuan Yang, Scott M Wasserman, Michael J Koren
Journal: Circulation (2013)

Background: AMG 145, a fully human monoclonal antibody against PCSK9, was well tolerated and significantly reduced low-density lipoprotein cholesterol (LDL-C) either as monotherapy or combined with other lipid-lowering agents in Phase 2 studies of 12 weeks’ duration. To date, longer-term safety and efficacy of AMG 145 in hypercholesterolemic patients in the absence of concomitant statin therapy have not been reported. Methods: We analyzed patients who completed the 12-week MENDEL study and agreed to participate in an open-label extension (OLE) study. MENDEL was a randomized, dose-ranging study that compared AMG 145 with placebo and ezetimibe in patients not on statin therapy with a 10-year Framingham risk score of ≤10%. Patients were randomized to 1 of 9 arms in approximately equal numbers: placebo, AMG 145 70, 105, or 140 mg SC every 2 weeks (Q2W); placebo, AMG 145 280, 350, or 420 mg SC every 4 weeks (Q4W); or ezetimibe 10 mg daily. OLE subjects were randomized to AMG 145 420 mg Q4W with standard of car...
Indomethacin-Induced, Monocyte-Dependent Restoration of Local Graft-Versus-Host Reaction Among Cells From Cancer Patients&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: G M Mavligit, L S Raphael, D B Calvo, W L Wong
Journal: JNCI Journal of the National Cancer Institute (1980)

Peripheral blood mononuclear cells from 16 of 17 cancer patients known to have a negative local graft-versus-host (GVH) reaction (T-cell function deficiency) were pharmacologically immunorestored by treatment with indomethacin. The restorative effect of the indomethacin was exerted directly on nonadherent lymphocytes. This process of desuppression required for its completion the presence of glass-adherent monocytes. The immune restorative effect of indomethacin in terms of local GVH reaction did not appear to be mediated by inhibition of prostaglandin synthesis. Pharmacologic immune restoration may be an important therapeutic modality in cancer patients.
Smokers are less likely than non-smokers to seek help for a lung cancer ‘alarm’ symptom
Authors: C Friedemann Smith, K L Whitaker, K Winstanley, J Wardle
Journal: Thorax (2016)

<h3>Background</h3> The majority (&gt;85%) of lung cancer cases are linked with smoking, and prognosis is poor because it is often diagnosed at a late stage. One contributor to late-stage diagnosis could be patient delay in help-seeking. We investigated the help-seeking behaviour of smokers and non-smokers for a recent lung cancer alarm symptom. <h3>Methods</h3> A health survey was sent to 4913 men and women aged &gt;50 years through through General Practice. It included questions on symptoms experienced in the past 3 months (from a checklist), help-seeking (Yes/No) for each symptom and demographic characteristics including smoking status. Univariable and multivariable binary logistic regression analyses were used to assess the association between smoking status and help-seeking for a cough or hoarseness. <h3>Results</h3> Among 2042 participants (42% response rate), 280 (14%) reported 'cough or hoarseness' in the past 3 months; of whom 22% were current smokers. Being a smoker was associated with reduced likelihood of help-seeking (OR 0.44; 95% CI 0.23 to 0.83), even after adjusting for demographic factors (OR 0.46; 95% CI 0.21 to 1.00). <h3>Conclusions</h3> Delay in help-seeking in smokers for a symptom that is potentially indicative of lung cancer is a cause for concern. Future research could usefully address the psychological mechanisms through which help-seeking in smokers is hindered.
Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Authors: C. Haioun, F. Morschhauser, E. Jourdan, J. Karsenti, G. Hess, U. Duehrsen, S. Kravchenko, G. van Hal, M. Hahka-Kemppinen
Journal: Journal of Clinical Oncology (2010)

8069 Background: PKC overexpression is observed in relapsed/refractory DLBCL. Enzastaurin (ENZ), an oral serine/threonine kinase inhibitor, targets PKCβ, and showed preclinical and clinical activity vs. DLBCL. Additionof ENZ may further improve salvage regimen such as R-GemOx in DLBCL pts not eligible for high-dose therapy (HDT). Methods: In this multicenter open-label, single-arm study patients (pts) with relapsed/refractory DLBCL who were not eligible for HDT and transplantation, received up to 8 cycles (cy) of R-GemOx plus ENZ followed by ENZ maintenance for max. 3 years. R-GemOx was administered in 2-weekly cy, with R 375 mg/m2 on day 1, Gem 1,000 mg/m2 and Ox 100 mg/m2 on day 2, plus ENZ 500 mg once daily, with an 1,125-mg loading dose on day 1 of cy 1. Only patients responding after 4 cy continued study treatment to receive 4 additional cy. Primary objective was 1-year progression free survival (PFS). Response rate and safety were secondary objectives. Results: A total of 68 pts with median age 69 years were enrolled between 2/2006 and 10/2008. 85% had received prior rituximab, 71% had only one prior line of chemotherapy, IPI score at relapse 0-2 vs 3-5 was 40% vs 60%. 65% of pts had an early relapse (≤ 12 months). 59% of pts completed more than 4 treatment cycles and 34% completed 8 cycles of therapy and continued with ENZ maintenance. Preliminary results after 4 cycles were: CR/CRu 13 (19%), PR 26 (38%), resulting in an ORR of 57% (CI 45-69%). Grade 3-4 neutropenia and thrombocytopenia were reported for 52% and 43% of the pts. At a max 10% of pts had a grade 3-4 infection during R-GemOx phase. Most common non-hematologic toxicity was neuropathy (4% gr 3). Toxicity during ENZ maintenance was mild: neutropenia 9%, anemia 4%. There were 3 deaths during R-GemOx phase that were possibly related to study drug (septic shock, CVA, ARDS). Conclusions: Given the patient characteristics,preliminary results of R-GemOx plus ENZ followed by ENZ maintenance treatment show an ORR in line with historical data (El Gnaoui, Ann Oncol 2007). Analysis of 1-year PFS rate is ongoing and will be reported. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Lilly Lilly
Lack of Multiplication of Ecotropic Murine C-Type Viruses in Mouse Teratocarcinoma Primitive Cells: Brief Communication2
Authors: J. Périès, E. Alves-Cardoso, M. Canivet, M. C. Debons-Guillemin, J. Lasneret
Journal: JNCI Journal of the National Cancer Institute (1977)

Ecotropic murine C-type viruses did not multiply in strain 129 mouse primitive teratocarcinoma cells cultivated in vitro. In contrast they replicated in differentiated cell lines derived from the same tumor.